OC-01 creatively adopts a transnasal delivery method, and is currently the world’s first and only preservative-free, multi-dose, aseptically packaged nasal spray approved for the treatment of mild, moderate and severe dry eye.
Chinese Expert Consensus on the Diagnosis and Treatment of Dry Eye (2024) recommends the use of recommended varenicline nasal sprays in ocular pro-secretor pharmacotherapy.
OC-01 was approved for marketing in October 2021 in the United States and in November 2024 in China.
Chinese Expert Consensus on the Diagnosis and Treatment of Dry Eye (2024) states that varenicline nasal sprays are highly selective cholinergic agonists, which activate the trigeminal parasympathetic pathway in the nose to stimulate secretion of the lacrimal glands, meibomian glands, and cupping cells, thereby increasing natural tear production.
